Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry/EMA Discuss Early Concerns Over EU’s Safety Signal Reporting Pilot

Executive Summary

Industry representatives have raised some issues around the EU’s pilot program for drug safety signal monitoring and reporting via the revamped EudraVigilance system.

You may also be interested in...



EMA Seeks To Extend EudraVigilance Pilot For Another Year

The pilot was launched to support a phased implementation of new EU requirements relating to monitoring and reporting drug safety information.

UK Regulator Promises Reasonable and Pragmatic Approach For EudraVigilance Inspections

Aware that marketing authorization holders are still finding their way around the EU’s revamped pharmacovigilance database – a UK inspector explains what procedures and processes companies should have in place to show compliance with new requirements to monitor and report safety signals.

Enhanced EudraVigilance System Goes Live, EMA Updates Info For Users

After months of preparations, the European Medicines Agency’s improved pharmacovigilance database has gone live on schedule.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS123070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel